Pharmaceuticals behemoth GlaxoSmithKline said its joint venture company, Shionogi-ViiV Healthcare, has completed an initial clinical registration package for dolutegravir, its treatment for HIV patients.
Phase III data required for initial regulatory filings for dolutegravir to be used on adults infected with HIV are now in house. Data from the two phase III studies in treatment-experienced patients (VIKING-3 and SAILING) will be the subject of future presentations at scientific meetings, Glaxo revealed.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Dolutegravir is not yet approved as a treatment for HIV or any other indication anywhere in the world.
The Shionogi-ViiV Healthcare joint venture was established between Shionogi,the Japanese pharmaceutical firm, ViiV Healthcare, a global company with a sole focus on HIV established in 2009 by Glaxo and US peer Pfizer.
Dolutegravir is the joint venture's flagship development drug but the company is also developing another integrase inhibitor - drugs which interfere with the role the enzyme integrase plays in HIV replication - which is at an earlier stage of development.
JH
-
Inflation holds steady at 3.8% ahead of BoE meetingThe rate of inflation did not rise in August, but the Bank of England is still expected to keep interest rates on hold tomorrow
-
Thousands of savers with £250k pensions take cash over tax-free money and IHT fearsWith a record £70 billion withdrawn from pensions in the year to March, experts are concerned savers are making knee-jerk decisions without advice that could affect their long term wealth
